Predictive value of circulating galectin-3 in patients with multiple myeloma in remission
DOI:
https://doi.org/10.14739/2310-1210.2015.4.50298Keywords:
galectin-3, Cardiovascular events, MultipleAbstract
Objective. We aimed to evaluate the prognostic value of circulating galectin-3 for cumulative survival in patients with multiple myeloma in full or partial remission.
Materials and methods. Eighty nine subjects with multiple myeloma in full or partial remission were enrolled into the study. Observation period was up to 12 months. Blood samples for biomarkers measurements were collected. Circulating level of galectin-3 was measured with ELISA method.
Results and Conclusions. Ninety two cumulative clinical events occurred in 36 patients (40.5%) within the follow-up, with their distribution being as follows: 8 cardiovascular deaths, 46 cardiac arrhythmias, 8 cardiac ischemic events, 2 strokes, 8 chronic heart failures and 22 hospital admissions for cardiovascular reasons. Medians of circulating levels of galectin-3 in free-events subject cohort and subjects cohort with cardiovascular events were 5.17 ng/ml (95% confidence interval [CI]=2.87–7.78 ng/ml) and 17.57 ng/ml (95% CI=11.36–23.79 ng/ml) (р<0.001). In multivariate logistic regression circulating galectin-3 independently predicted cumulative cardiovascular events (odds ratio [OR]=1.10; 95% CI=1.01–1.13; р = 0.001) within 12 months of observation period.
Among patients with documented multiple myeloma in remission increased circulating galectin-3 associates with increased cumulative cardiovascular events.
References
Aue, G., Nelson Lozier, J., Tian, X., Cullinane, A. M., Soto, S., Samsel, L., et al. (2011) Inflammation, TNFα and endothelial dysfunction link lenalidomide to venous thrombosis in chronic lymphocytic leukemia. Am. J. Hematol., 86(10), 835–840. doi: 10.1002/ajh.22114.
Bi, S., Earl, L. A., Jacobs, L., & Baum, L. G. (2008) Structural features of galectin-9 and galectin-1 that determine distinct T cell death pathways. J. Biol. Chem., 283(18), 12248–12258. doi: 10.1074/jbc.M800523200.
Clark, M. C., Pang, M., Hsu, D. K., Liu, F. T., de Vos, S., Gascoyne, R. D., et al. (2012) Galectin-3 binds to CD45 on diffuse large B-cell lymphoma cells to regulate susceptibility to cell death. Blood, 120(23), 4635–4644. doi: 10.1182/blood-2012-06-438234. E.
Croci, D. O., Morande, P. E., Dergan-Dylon, S., Borge, M., Toscano, M. A., Stupirski, J. C., et al. (2013) Nurse-like cells control the activity of chronic lymphocytic leukemia B cells via galectin-1. Leukemia, 27(6), 1413–1436. doi: 10.1038/leu.2012.315.
Dimopoulos, M. A., & Terpos, E. (2010) Multiple myeloma. Ann. Oncol., 21(Suppl. 7), 143–150.
Fortuna-Costa, A., Gomes, A. M., Kozlowski, E. O., Stelling, M. P., Pavão, M. S. (2014) Extracellular galectin-3 in tumor progression and metastasis. Front. Oncol., 16(4), 138. doi: 10.3389/fonc.2014.00138.
Gardin, J. M., Adams, D. B., Douglas, P. S., Feigenbaum, H., Forst, D. H., Fraser, A. G., et al. (2002) Recommendations for a standardized report for adult transthoracic echocardiography: a reportfrom the American Society of Echocardiography's Nomenclature and Standards Committee and Task Force for a Standardized Echocardiography Report. American Society of Echocardiography. Recommendations for a standardized report for adult transthoracic echocardiography: a report from the American Society of Echocardiography's Nomenclature and Standards Committee and Task Force for a Standardized Echocardiography Report J. Am. Soc. Echocardiogr., 15(3), 275–290.
Giordano, S. M., Croci, G. A., & Rabinovich, G. A. (2013) Galectins in hematological malignancies. Curr. Opin. Hematol., 20(4), 327–335. doi: 10.1097/MOH.0b013e328362370f.
Gruson, D., & Ko Gruson, G. D. (2012) Galectins testing: new promises for the diagnosis and risk stratification of chronic diseases? Clin. Biochem., 45(10–11), 719 – 726. doi: 10.1016/j.clinbiochem.2012.04.009.
Hoyer, K. K., Pang, M., Gui, D., Shintaku, I. P., Kuwabara, I., Liu, F.T., et al. (2004) An anti-apoptotic role for galectin-3 in diffuse large B-cell lymphomas. Am. J. Pathol., 164, 893–902. doi: 10.1016/S0002-9440(10)63177-X.
Kim, S. J., Lee, S. J., Sung, H. J., Choi, I. K., Choi, C. W., Kim, B. S., et al. (2008) Increased serum 90K and Galectin-3 expression are associated with advanced stage and a worse prognosis in diffuse large B-cell lymphomas. Acta Haematol., 120(4), 211–216. doi: 10.1159/000193223.
Menini, S., Iacobini, C., Ricci, C., Blasetti Fantauzzi, C., Salvi, L., Pesce, C. M., et al. (2013) The galectin-3/RAGE dyad modulates vascular osteogenesis in atherosclerosis. Cardiovasc. Res., 100(3), 472–480. doi: 10.1093/cvr/cvt206.
Mikhael, J. R., Dingli, D., Roy, V., Reeder, C. B., Buadi, F. K., Hayman, S. R., et al. (2013) Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines. Mayo Clin Proc., 88(7), 360–376. doi: 10.1016/j.mayocp.2013.01.019.
Mirandola, L., Nguyen, D. D., Rahman, R. L., Grizzi, F., Yuefei, Y., Figueroa, J. A., et al. (2014) Anti-Galectin-3 Therapy: A New Chance for Multiple Myeloma and Ovarian Cancer? Int. Rev. Immunol., 33(5), 417–427. doi: 10.3109/08830185.2014.911855.
Moreau, P., San Miguel, J., Ludwig, H., Schouten, H., Mohty, M., Dimopoulos, M., & Dreyling, M. (2013) ESMO Guidelines Working Group. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol., 24(6), 133–137. doi: 10.1093/annonc/mdt297
Osborne, T. R., Ramsenthaler, C., de Wolf-Linder, S., Schey, S. A., Siegert, R. J., Edmonds, P. M., & Higginson, I. J. (2014) Understanding what matters most to people with multiple myeloma: a qualitative study of views on quality of life. BMC Cancer, 9(14), 496. doi: 10.1186/1471-2407-14-496.
Streetly, M. J., Maharaj, L., Joel, S., Schey, S. A., Gribben, J. G., & Cotter, F. E. (2010) GCS-100, a novel galectin-3 antagonist, modulates MCL-1, NOXA, and cell cycle to induce myeloma cell death. Blood, 115(19), 3939–3948. doi: 10.1182/blood-2009-10-251660.
Downloads
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
